SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-005169
Filing Date
2024-01-22
Accepted
2024-01-22 12:01:23
Documents
15
Period of Report
2024-01-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea191848-8k_elevailabs.htm   iXBRL 8-K 41558
2 LICENSE AGREEMENT, DATED JANUARY 16, 2024, BY AND BETWEEN THE COMPANY AND INMUNE ea191848ex10-1_elevailabs.htm EX-10.1 66793
3 PRESS RELEASE OF THE COMPANY DATED AS OF NOVEMBER 29, 2023 ea191848ex99-1_elevailabs.htm EX-99.1 12253
4 GRAPHIC ex99-1_001.jpg GRAPHIC 2797
  Complete submission text file 0001213900-24-005169.txt   324187

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE elab-20240116.xsd EX-101.SCH 3030
6 XBRL LABEL FILE elab-20240116_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE elab-20240116_pre.xml EX-101.PRE 22369
9 EXTRACTED XBRL INSTANCE DOCUMENT ea191848-8k_elevailabs_htm.xml XML 3411
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

IRS No.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 24547628
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)